Plasma concentrations of benzodiazepines.
1. Twenty anxious patients were treated with medazepam, diazepam, chlordiazepoxide, amylobarbitone and placebo, each given in flexible dosage for 2-4 weeks. 2. At the end of each treatment, a series of clinical, physiological and behavioural variables were measured and plasma samples were taken for estimation of the appropriate drug and metabolite concentrations. 3. Nordiazepam was shown to be an important metabolite of both medazepam and diazepam: the ratio of medazepam to noradiazepam was 0.14 and the ratio of diazepam to nordiazepam following diazepam administration was 0.72. 4. No significant correlations were found between the plasma concentrations of any of the treatments and the clinical ratings or behavioural measures. 5. Some relationship was shown between levels of medazepam and its physiological effects.
D000654:Amobarbital / Q000097:blood; D014151:Anti-Anxiety Agents / Q000097:blood*; D002707:Chlordiazepoxide / Q000097:blood; D003975:Diazepam / Q000097:blood; D006801:Humans; D008472:Medazepam / Q000097:blood; D013997:Time Factors
D014151:Anti-Anxiety Agents; D002707:Chlordiazepoxide; D000654:Amobarbital; D008472:Medazepam; D003975:Diazepam